NRx Pharmaceuticals, Inc. (NRXP), a clinical-stage biopharmaceutical firm, announced on Monday the appointment of Michael Abrams as the company's permanent Chief Financial Officer. Abrams succeeds Interim CFO Richard Narido, who will continue to play a supportive role in the company's financial operations and other initiatives.
Dr. Jonathan Javitt, Chairman, CEO, and Chief Scientist of NRx Pharmaceuticals, expressed enthusiasm about the new appointment, stating, "We are pleased to have Mike join the NRx team. His blend of public company CFO experience within the biotechnology sector, along with his investment banking expertise, is perfectly aligned with NRx's aspirations as we strive to evolve into a revenue-generating, profitable biotechnology enterprise."
Michael Abrams brings nearly three decades of experience as a senior finance professional, having previously held roles as an executive officer, investment banker, director, and senior advisor. His past positions include Chief Financial Officer at Arch Therapeutics, RiseIT Solutions, and FitLife Brands.